<!DOCTYPE html>
<html lang="en" data-arca>
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Acute Myeloid Leukemia BRA â€” ArcaScience | Targeted Therapies &amp; Venetoclax</title>
  <meta name="description" content="AI-driven benefit-risk analysis for Acute Myeloid Leukemia covering venetoclax combinations, FLT3 inhibitors, IDH inhibitors, and gemtuzumab ozogamicin. ArcaScience models tumor lysis syndrome, differentiation syndrome, and treatment-related mortality in elderly AML patients.">

  <link rel="preload" href="/fonts/Inter-Variable.woff2" as="font" type="font/woff2" crossorigin>
  <link rel="preload" href="/fonts/Literata-Variable.woff2" as="font" type="font/woff2" crossorigin>
  <link rel="stylesheet" href="/dist/arcascience-global.min.css">

  <script>
    (function(){
      if(window.matchMedia&&window.matchMedia('(prefers-reduced-motion: reduce)').matches){
        document.documentElement.classList.add('reduced-motion');
      }
    })();
  </script>
</head>
<body>

  <div data-scroll-progress></div>

  <!-- NAVIGATION -->
  <nav class="arca-nav" data-nav="sticky" role="navigation" aria-label="Main navigation">
    <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px; display: flex; align-items: center; justify-content: space-between; height: 100%;">
      <a href="/" aria-label="ArcaScience home">
        <img src="/images/arcascience-logo.svg" alt="ArcaScience" height="32">
      </a>
      <div style="display: flex; align-items: center; gap: 32px;">
        <a href="/" class="arca-nav-link">Home</a>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/platform-overview" class="arca-nav-link">Platform <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; left: -12px; min-width: 260px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/platform-overview" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Platform Overview</a>
            <a href="/platform-how-it-works" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">How It Works</a>
            <a href="/platform-data-intelligence" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Data Intelligence</a>
            <a href="/platform-ai-models" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">AI Models</a>
            <a href="/platform-outputs" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Regulatory Outputs</a>
            <a href="/platform-integrations" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Integrations</a>
            <div style="height: 1px; background: linear-gradient(90deg, transparent, rgba(35,86,160,0.15), transparent); margin: 6px 12px;"></div>
            <a href="/security-compliance" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Security &amp; Compliance</a>
          </div>
        </div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/solution-therapeutic-area" class="arca-nav-link is-active">Solutions <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; left: -12px; min-width: 260px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <p style="padding: 6px 16px 4px; font-size: 0.6875rem; font-weight: 600; letter-spacing: 0.08em; text-transform: uppercase; color: var(--grey-400); margin: 0;">By Approach</p>
            <a href="/solution-therapeutic-area" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">By Therapeutic Area</a>
            <a href="/solution-lifecycle-phase" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">By Lifecycle Phase</a>
            <a href="/solution-role" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">By Role</a>
            <div style="height: 1px; background: linear-gradient(90deg, transparent, rgba(35,86,160,0.15), transparent); margin: 6px 12px;"></div>
            <p style="padding: 6px 16px 4px; font-size: 0.6875rem; font-weight: 600; letter-spacing: 0.08em; text-transform: uppercase; color: var(--grey-400); margin: 0;">By Stage</p>
            <a href="/solution-early-development" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Early Development</a>
            <a href="/solution-late-development" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Late Development</a>
            <a href="/solution-post-marketing" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Post-Marketing</a>
            <a href="/solution-market-access" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Market Access</a>
            <div style="height: 1px; background: linear-gradient(90deg, transparent, rgba(35,86,160,0.15), transparent); margin: 6px 12px;"></div>
            <p style="padding: 6px 16px 4px; font-size: 0.6875rem; font-weight: 600; letter-spacing: 0.08em; text-transform: uppercase; color: var(--grey-400); margin: 0;">Therapeutic Areas</p>
            <a href="/ta-oncology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Oncology</a>
            <a href="/ta-neurology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Neurology</a>
            <a href="/ta-immunology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Immunology</a>
            <a href="/ta-cardiology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Cardiology</a>
            <a href="/ta-respiratory" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Respiratory</a>
            <a href="/ta-rare-diseases" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Rare Diseases</a>
          </div>
        </div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/evidence-case-studies-hub" class="arca-nav-link">Evidence <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; left: -12px; min-width: 220px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/evidence-case-studies-hub" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Case Studies</a>
            <a href="/evidence-publications" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Publications</a>
            <a href="/evidence-metrics" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Platform Metrics</a>
          </div>
        </div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/about" class="arca-nav-link">Company <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; left: -12px; min-width: 200px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/about" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">About ArcaScience</a>
            <a href="/leadership" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Leadership</a>
            <a href="/careers" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Careers</a>
            <a href="/science-methodology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Science &amp; Methodology</a>
          </div>
        </div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/resources" class="arca-nav-link">Resources <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; right: -12px; min-width: 220px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/resources" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Resource Hub</a>
            <a href="/resources-whitepapers" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Whitepapers</a>
            <a href="/resources-webinars" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Webinars &amp; Events</a>
            <div style="height: 1px; background: linear-gradient(90deg, transparent, rgba(35,86,160,0.15), transparent); margin: 6px 12px;"></div>
            <a href="/resources-faq" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">FAQ</a>
            <a href="/resources-glossary" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px; transition: background 150ms ease;">Glossary</a>
          </div>
        </div>
      </div>
      <a href="/contact" class="arca-btn-primary" style="height: 40px; padding: 8px 24px; font-size: 0.875rem;">Talk to a Scientist</a>
    </div>
  </nav>

  <div style="height: var(--nav-height);"></div>

  <main role="main">

    <!-- HERO -->
    <section class="arca-bg-blue-900" style="position: relative; overflow: hidden; padding: var(--space-8) 0 var(--space-9);" data-animate>
      <div style="position: absolute; top: -100px; right: -100px; width: 500px; height: 500px; background: radial-gradient(circle, rgba(79, 70, 229, 0.12) 0%, transparent 70%); border-radius: 50%; filter: blur(60px); pointer-events: none; animation: as-float 8s ease-in-out infinite; z-index: 0;"></div>
      <div style="position: absolute; bottom: -80px; left: -80px; width: 400px; height: 400px; background: radial-gradient(circle, rgba(34, 197, 94, 0.06) 0%, transparent 70%); border-radius: 50%; filter: blur(60px); pointer-events: none; animation: as-float 10s ease-in-out infinite reverse; z-index: 0;"></div>

      <svg width="420" height="320" viewBox="0 0 420 320" fill="none" aria-hidden="true" style="position: absolute; right: -20px; top: 50%; transform: translateY(-50%); opacity: 0.12; pointer-events: none; z-index: 0;">
        <circle cx="210" cy="160" r="16" stroke="rgba(79,70,229,0.5)" stroke-width="1.5" fill="none"/>
        <circle cx="210" cy="160" r="6" fill="rgba(79,70,229,0.3)"/>
        <circle cx="290" cy="100" r="10" stroke="rgba(34,197,94,0.4)" stroke-width="1" fill="none"/>
        <circle cx="130" cy="100" r="10" stroke="rgba(34,197,94,0.4)" stroke-width="1" fill="none"/>
        <circle cx="290" cy="220" r="10" stroke="rgba(79,70,229,0.4)" stroke-width="1" fill="none"/>
        <circle cx="130" cy="220" r="10" stroke="rgba(79,70,229,0.4)" stroke-width="1" fill="none"/>
        <line x1="210" y1="160" x2="290" y2="100" stroke="rgba(79,70,229,0.3)" stroke-width="1.5"/>
        <line x1="210" y1="160" x2="130" y2="100" stroke="rgba(34,197,94,0.3)" stroke-width="1.5"/>
        <line x1="210" y1="160" x2="290" y2="220" stroke="rgba(79,70,229,0.3)" stroke-width="1.5"/>
        <line x1="210" y1="160" x2="130" y2="220" stroke="rgba(34,197,94,0.3)" stroke-width="1.5"/>
      </svg>

      <div style="position: relative; z-index: 1; max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <nav aria-label="Breadcrumb" style="margin-bottom: var(--space-5);">
          <ol style="list-style: none; padding: 0; margin: 0; display: flex; align-items: center; gap: 8px; font-size: 0.75rem;">
            <li><a href="/" style="color: rgba(255,255,255,0.65); text-decoration: none;">Home</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li><a href="/solution-therapeutic-area" style="color: rgba(255,255,255,0.65); text-decoration: none;">Therapeutic Areas</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li><a href="/ta-hematology" style="color: rgba(255,255,255,0.65); text-decoration: none;">Hematology</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li style="color: var(--white);">Acute Myeloid Leukemia</li>
          </ol>
        </nav>

        <div style="max-width: 820px;">
          <p class="arca-label arca-text-blue-400" style="margin-bottom: var(--space-3);">Hematology &rsaquo; Acute Myeloid Leukemia</p>
          <h1 class="arca-display-lg arca-text-white" style="margin-bottom: var(--space-5);">
            AI-Driven Benefit-Risk Analysis for Acute Myeloid Leukemia
          </h1>
          <p class="arca-body-lg" style="color: rgba(255,255,255,0.85); max-width: 680px; margin-bottom: var(--space-7);">
            AML BRA spans venetoclax-based combinations, FLT3 inhibitors (midostaurin, gilteritinib), IDH1/2 inhibitors (ivosidenib, enasidenib), and gemtuzumab ozogamicin. ArcaScience delivers mutation-directed safety profiling across fit and unfit patient populations, with specialized models for tumor lysis syndrome, differentiation syndrome, and treatment-related mortality in elderly patients.
          </p>
          <div style="display: flex; gap: 16px; flex-wrap: wrap;">
            <a href="/platform-overview" class="arca-btn-primary-inverted">See Platform</a>
            <a href="/contact?disease=aml" class="arca-btn-secondary" style="border-color: rgba(255,255,255,0.3); color: var(--white);">Request Demo</a>
          </div>
        </div>
      </div>
    </section>

    <!-- KEY STATISTICS -->
    <section class="arca-credibility-bar" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="display: grid; grid-template-columns: repeat(4, 1fr); gap: 32px; text-align: center;">
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="160000" data-countup-suffix="+">0</span>
            <p class="arca-caption">New AML cases per year globally</p>
          </div>
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="1500" data-countup-suffix="+">0</span>
            <p class="arca-caption">AML clinical trials analyzed</p>
          </div>
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="4" data-countup-suffix="B">$0</span>
            <p class="arca-caption">Global AML therapeutics market</p>
          </div>
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="10" data-countup-suffix="+">0</span>
            <p class="arca-caption">Targeted AML agents approved since 2017</p>
          </div>
        </div>
      </div>
    </section>

    <!-- DISEASE OVERVIEW -->
    <section style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="max-width: 720px; margin: 0 auto 48px; text-align: center;">
          <p class="arca-section-label">Disease Overview</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-5);">Why AML Demands Specialized BRA</h2>
          <p class="arca-body-lg arca-text-grey-600">
            AML is a genetically heterogeneous malignancy where molecular profiling (FLT3, IDH1/2, NPM1, TP53, RUNX1) dictates treatment selection. The median age at diagnosis is 68 years, and the majority of patients are ineligible for intensive chemotherapy, creating a critical need for BRA that balances efficacy against treatment-related mortality in frail and comorbid populations.
          </p>
        </div>

        <div style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 24px;">
          <div class="arca-card" data-animate="slide-up">
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Tumor Lysis Syndrome with Venetoclax</h3>
            <p class="arca-body-sm arca-text-grey-600">
              Venetoclax combined with azacitidine or low-dose cytarabine has become standard of care for unfit AML patients, but carries significant tumor lysis syndrome (TLS) risk requiring mandatory dose ramp-up over 3&ndash;4 days with hospitalization. BRA must model TLS incidence by baseline white blood cell count, renal function, and tumor burden, alongside the ramp-up protocol's impact on early mortality and treatment delay.
            </p>
          </div>
          <div class="arca-card" data-animate="slide-up">
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">QTc Prolongation &amp; FLT3 Inhibitor Safety</h3>
            <p class="arca-body-sm arca-text-grey-600">
              Gilteritinib carries QTc prolongation risk requiring ECG monitoring, while midostaurin combined with intensive chemotherapy increases febrile neutropenia severity and duration. BRA for FLT3-mutated AML must account for drug-drug interactions with azole antifungals (CYP3A4), the cardiac safety profile during prolonged maintenance therapy, and comparative safety between type I and type II FLT3 inhibitors.
            </p>
          </div>
          <div class="arca-card" data-animate="slide-up">
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Differentiation Syndrome with IDH Inhibitors</h3>
            <p class="arca-body-sm arca-text-grey-600">
              Ivosidenib (IDH1) and enasidenib (IDH2) can induce differentiation syndrome in 10&ndash;20% of patients, a potentially fatal complication resembling retinoic acid syndrome in APL. BRA must model early recognition, dexamethasone intervention, and the benefit-risk of continuing therapy through differentiation syndrome events versus treatment discontinuation, alongside hepatotoxicity monitoring for ivosidenib.
            </p>
          </div>
        </div>
      </div>
    </section>

    <!-- ARCASCIENCE APPROACH -->
    <div class="arca-section-divider" aria-hidden="true"></div>

    <section class="arca-bg-grey-50 arca-bg-dots" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="text-align: center; margin-bottom: var(--space-8);">
          <p class="arca-section-label">Platform Capabilities</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-4);">How ArcaScience Addresses AML BRA</h2>
          <p class="arca-body-lg arca-text-grey-600" style="max-width: 680px; margin: 0 auto;">
            Our platform integrates mutation-specific AML data, elderly/unfit patient risk models, and regulatory templates aligned with hematologic oncology submission requirements across FDA, EMA, and accelerated approval pathways.
          </p>
        </div>

        <div style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 24px;">
          <div class="arca-card arca-card-colored-top is-data" data-animate="slide-up">
            <span class="arca-module-tag is-data">Data Intelligence</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">AML Data Coverage</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">
              1,500+ AML clinical trials including VIALE-A, ADMIRAL, RATIFY, AGILE, and BRIGHT AML 1003 datasets. Adverse event data covering venetoclax TLS, gilteritinib QTc prolongation, IDH inhibitor differentiation syndrome, gemtuzumab ozogamicin hepatic sinusoidal obstruction syndrome, and intensive chemotherapy treatment-related mortality across all cytogenetic and molecular risk groups.
            </p>
            <a href="/platform-data-intelligence" class="arca-btn-tertiary">Explore Data Engine <span class="arca-arrow">&rarr;</span></a>
          </div>

          <div class="arca-card arca-card-colored-top is-analytics" data-animate="slide-up">
            <span class="arca-module-tag is-analytics">Decision Intelligence</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">Mutation-Directed AI Models</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">
              AI models for TLS risk stratification during venetoclax ramp-up, differentiation syndrome early detection for IDH-mutated patients, QTc modeling during FLT3 inhibitor therapy, and treatment-related mortality prediction using fitness assessment scores (ECOG, HCT-CI). BRAT framework application with AML-specific regulatory precedent from ODAC deliberations on accelerated approvals and confirmatory trial design.
            </p>
            <a href="/platform-ai-models" class="arca-btn-tertiary">Explore AI Models <span class="arca-arrow">&rarr;</span></a>
          </div>

          <div class="arca-card arca-card-colored-top is-output" data-animate="slide-up">
            <span class="arca-module-tag is-output">Automated Outputs</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">AML Regulatory Outputs</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">
              PSURs with TLS and differentiation syndrome deep-dives, RMPs with cardiac monitoring protocols for FLT3 inhibitors and hepatotoxicity surveillance for GO and IDH inhibitors, CTD 2.5 with CR/CRi, OS, and MRD endpoint summaries, and HEOR reports supporting reimbursement submissions for targeted therapies in mutation-defined AML subpopulations.
            </p>
            <a href="/platform-outputs" class="arca-btn-tertiary">Explore Outputs <span class="arca-arrow">&rarr;</span></a>
          </div>
        </div>
      </div>
    </section>

    <!-- KEY METRICS -->
    <section class="arca-bg-blue-50 arca-bg-mesh" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="text-align: center; margin-bottom: var(--space-8);">
          <p class="arca-section-label">AML Intelligence</p>
          <h2 class="arca-display-sm">Platform Performance in AML</h2>
        </div>
        <div style="display: grid; grid-template-columns: repeat(4, 1fr); gap: 32px; text-align: center;">
          <div>
            <span class="arca-stat-lg" style="color: var(--indigo-600);" data-countup="6200000000" data-countup-suffix="+">0</span>
            <p class="arca-caption arca-text-grey-600">AML adverse event data points</p>
          </div>
          <div>
            <span class="arca-stat-lg" style="color: var(--indigo-600);" data-countup="65" data-countup-suffix="%">0</span>
            <p class="arca-caption arca-text-grey-600">Faster TLS risk signal identification</p>
          </div>
          <div>
            <span class="arca-stat-lg" style="color: var(--indigo-600);" data-countup="8">0</span>
            <p class="arca-caption arca-text-grey-600">Molecular subtypes modeled</p>
          </div>
          <div>
            <span class="arca-stat-lg" style="color: var(--indigo-600);" data-countup="6">0</span>
            <p class="arca-caption arca-text-grey-600">AML submissions supported</p>
          </div>
        </div>
      </div>
    </section>

    <!-- CASE EVIDENCE -->
    <section style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 64px; align-items: center;">
          <div>
            <p class="arca-section-label">Case Evidence &mdash; AML</p>
            <h2 class="arca-heading-1" style="margin-bottom: var(--space-5);">Venetoclax-Based Regimen Safety Optimization in Unfit Elderly AML</h2>
            <div style="margin-bottom: var(--space-5);">
              <h3 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Challenge</h3>
              <p class="arca-body-sm arca-text-grey-600">A pharma company developing a venetoclax combination regimen for elderly AML patients (median age 76, ECOG 2&ndash;3) needed to model the benefit-risk of their TLS prophylaxis protocol alongside treatment-related mortality rates across comorbidity strata. Regulatory agencies required evidence that the ramp-up schedule and hospitalization requirements were optimized for this fragile population.</p>
            </div>
            <div style="margin-bottom: var(--space-5);">
              <h3 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Result</h3>
              <p class="arca-body-sm arca-text-grey-600">ArcaScience deployed TLS risk stratification models integrating baseline WBC count, LDH, renal function, and bone marrow blast percentage, enabling patient-level risk scoring that guided individualized ramp-up durations. The BRA identified a subpopulation where outpatient ramp-up was feasible, reducing hospitalization burden while maintaining TLS safety. Early mortality modeling supported optimized dose modification guidelines accepted by both FDA and EMA.</p>
            </div>
            <div style="display: grid; grid-template-columns: repeat(2, 1fr); gap: 24px; margin-bottom: var(--space-6);">
              <div>
                <span class="arca-stat-sm" style="color: var(--indigo-600);" data-countup="2.5" data-countup-suffix="x">0</span>
                <p class="arca-caption arca-text-grey-600">Faster TLS risk stratification</p>
              </div>
              <div>
                <span class="arca-stat-sm" style="color: var(--indigo-600);" data-countup="35" data-countup-suffix="%">0</span>
                <p class="arca-caption arca-text-grey-600">Reduction in early treatment-related mortality uncertainty</p>
              </div>
            </div>
            <a href="/evidence-case-studies-hub" class="arca-btn-tertiary">View All Case Studies <span class="arca-arrow">&rarr;</span></a>
          </div>

          <div class="arca-testimonial" style="text-align: left;">
            <div class="arca-testimonial-quote" style="padding-left: 24px; border-left: 3px solid var(--blue-400);">
              The ability to model treatment-related mortality across comorbidity strata was exactly what we needed for our elderly AML population. ArcaScience's TLS risk stratification directly informed our revised ramp-up protocol, and the data-driven approach gave regulators confidence in our outpatient dosing proposal for lower-risk patients.
            </div>
            <div class="arca-testimonial-attribution" style="margin-top: var(--space-5);">
              <p class="arca-body-md" style="font-weight: 600;">Head of Hematology Clinical Safety</p>
              <p class="arca-body-sm arca-text-grey-600">Global Pharma Company</p>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- FAQ ACCORDION -->
    <div class="arca-section-divider" aria-hidden="true"></div>

    <section class="arca-bg-teal-100 arca-bg-rings" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="max-width: 720px; margin: 0 auto 48px; text-align: center;">
          <p class="arca-section-label">Frequently Asked Questions</p>
          <h2 class="arca-display-sm">AML Benefit-Risk Analysis</h2>
        </div>
        <div style="max-width: 820px; margin: 0 auto;">
          <div data-accordion="group">
            <div data-accordion-item style="border-bottom: 1px solid var(--grey-200);">
              <button data-accordion-trigger aria-expanded="false" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">How does ArcaScience support mutation-directed therapy BRA in AML?</h3>
                <svg data-accordion-icon width="16" height="16" viewBox="0 0 16 16" fill="none" style="flex-shrink: 0;"><path d="M4 6l4 4 4-4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg>
              </button>
              <div data-accordion-content aria-hidden="true" style="max-height: 0; overflow: hidden; transition: max-height 300ms ease-out;">
                <div style="padding: 0 0 var(--space-5);"><p class="arca-body-sm arca-text-grey-600">Our platform stratifies BRA by molecular subtype. For FLT3-ITD and FLT3-TKD mutations, we model midostaurin (induction) and gilteritinib (relapsed/refractory) safety including QTc prolongation and CYP3A4-mediated drug interactions. For IDH1-mutated AML, ivosidenib BRA covers differentiation syndrome and hepatotoxicity. For IDH2 mutations, enasidenib BRA includes differentiation syndrome and indirect hyperbilirubinemia. Each molecular subgroup receives tailored benefit metrics (CR/CRi rate, OS, MRD negativity) weighed against mutation-specific and regimen-specific adverse events, reflecting the ELN 2022 risk classification framework.</p></div>
              </div>
            </div>
            <div data-accordion-item style="border-bottom: 1px solid var(--grey-200);">
              <button data-accordion-trigger aria-expanded="false" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">How does the platform assess risk in elderly and unfit AML patients?</h3>
                <svg data-accordion-icon width="16" height="16" viewBox="0 0 16 16" fill="none" style="flex-shrink: 0;"><path d="M4 6l4 4 4-4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg>
              </button>
              <div data-accordion-content aria-hidden="true" style="max-height: 0; overflow: hidden; transition: max-height 300ms ease-out;">
                <div style="padding: 0 0 var(--space-5);"><p class="arca-body-sm arca-text-grey-600">ArcaScience integrates fitness assessment scores (ECOG PS, HCT-CI, Wheatley index) with age, organ function, and cytogenetic risk to model treatment-related mortality (TRM) across regimen intensity levels. For venetoclax + azacitidine in patients &ge;75 years with ECOG 2&ndash;3, the platform models 30-day and 60-day TRM alongside CR/CRi rates and OS. For patients on the cusp of fitness for intensive chemotherapy, we provide comparative BRA between intensive 7+3 and lower-intensity venetoclax-based approaches, helping clinicians and regulators assess whether intensive therapy's higher TRM is justified by superior remission depth.</p></div>
              </div>
            </div>
            <div data-accordion-item style="border-bottom: 1px solid var(--grey-200);">
              <button data-accordion-trigger aria-expanded="false" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">Does the platform model transplant conditioning safety for AML?</h3>
                <svg data-accordion-icon width="16" height="16" viewBox="0 0 16 16" fill="none" style="flex-shrink: 0;"><path d="M4 6l4 4 4-4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg>
              </button>
              <div data-accordion-content aria-hidden="true" style="max-height: 0; overflow: hidden; transition: max-height 300ms ease-out;">
                <div style="padding: 0 0 var(--space-5);"><p class="arca-body-sm arca-text-grey-600">Yes. Our platform covers allogeneic stem cell transplant conditioning BRA including myeloablative (MAC) versus reduced-intensity conditioning (RIC) safety profiles. We model graft-versus-host disease (GVHD) incidence and severity, veno-occlusive disease/sinusoidal obstruction syndrome risk, non-relapse mortality, and the benefit-risk of novel GVHD prophylaxis regimens (post-transplant cyclophosphamide, abatacept). The BRA integrates pre-transplant fitness, donor type, and conditioning intensity to provide individualized transplant safety assessments.</p></div>
              </div>
            </div>
            <div data-accordion-item style="border-bottom: 1px solid var(--grey-200);">
              <button data-accordion-trigger aria-expanded="false" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">How does ArcaScience model maintenance therapy BRA in AML?</h3>
                <svg data-accordion-icon width="16" height="16" viewBox="0 0 16 16" fill="none" style="flex-shrink: 0;"><path d="M4 6l4 4 4-4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg>
              </button>
              <div data-accordion-content aria-hidden="true" style="max-height: 0; overflow: hidden; transition: max-height 300ms ease-out;">
                <div style="padding: 0 0 var(--space-5);"><p class="arca-body-sm arca-text-grey-600">AML maintenance therapy is an evolving paradigm with oral azacitidine (CC-486/ONUREG) now established post-intensive chemotherapy. Our platform models the benefit-risk of prolonged maintenance including cumulative cytopenias, gastrointestinal toxicity, quality-of-life impact, and relapse-free survival benefit. For FLT3-mutated AML, we model post-transplant sorafenib or gilteritinib maintenance safety including prolonged QTc exposure risk and drug interaction management with immunosuppressants. The BRA accounts for the critical question of maintenance duration optimization.</p></div>
              </div>
            </div>
            <div data-accordion-item>
              <button data-accordion-trigger aria-expanded="false" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">Can ArcaScience support MRD-guided treatment decisions in AML BRA?</h3>
                <svg data-accordion-icon width="16" height="16" viewBox="0 0 16 16" fill="none" style="flex-shrink: 0;"><path d="M4 6l4 4 4-4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg>
              </button>
              <div data-accordion-content aria-hidden="true" style="max-height: 0; overflow: hidden; transition: max-height 300ms ease-out;">
                <div style="padding: 0 0 var(--space-5);"><p class="arca-body-sm arca-text-grey-600">Yes. Measurable residual disease (MRD) is increasingly used as an early efficacy endpoint and treatment decision tool in AML. ArcaScience models the benefit-risk implications of MRD-guided therapy escalation (e.g., proceeding to transplant for MRD-positive patients) versus de-escalation (e.g., omitting transplant for MRD-negative favorable-risk patients). The platform integrates multiparameter flow cytometry and molecular MRD data (NPM1, CBF) to assess whether MRD-directed treatment modifications alter the safety profile acceptably relative to relapse risk reduction, supporting both clinical trial design and regulatory discussions around MRD as a surrogate endpoint.</p></div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- CTA -->
    <section class="arca-cta-section" data-animate style="position: relative; overflow: hidden;">
      <div style="position: absolute; top: -60px; left: -60px; width: 300px; height: 300px; background: radial-gradient(circle, rgba(255,255,255,0.08) 0%, transparent 70%); border-radius: 50%; filter: blur(40px); pointer-events: none; animation: as-float 7s ease-in-out infinite; z-index: 0;"></div>
      <div style="position: absolute; bottom: -40px; right: -40px; width: 250px; height: 250px; background: radial-gradient(circle, rgba(255,255,255,0.06) 0%, transparent 70%); border-radius: 50%; filter: blur(40px); pointer-events: none; animation: as-float 9s ease-in-out infinite reverse; z-index: 0;"></div>
      <div style="position: relative; z-index: 1; max-width: 680px; margin: 0 auto; padding: 0 24px;">
        <h2 class="arca-heading-1" style="margin-bottom: var(--space-5);">See ArcaScience Applied to AML</h2>
        <p class="arca-body-lg" style="margin-bottom: var(--space-7);">Request a demonstration of ArcaScience's platform configured for acute myeloid leukemia benefit-risk analysis. Our hematology scientists will walk through mutation-specific data coverage, TLS and differentiation syndrome models, elderly patient risk assessment, and regulatory output examples.</p>
        <div style="display: flex; gap: 16px; justify-content: center; flex-wrap: wrap;">
          <a href="/contact?disease=aml" class="arca-btn-primary-inverted">Request AML Briefing</a>
          <a href="/platform-overview" class="arca-btn-secondary" style="border-color: rgba(255,255,255,0.3); color: var(--white);">Explore the Platform <span class="arca-arrow">&rarr;</span></a>
        </div>
      </div>
    </section>

  </main>

  <!-- FOOTER -->
  <footer class="arca-bg-blue-900" style="padding: var(--space-9) 0 var(--space-7);">
    <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
      <div style="display: grid; grid-template-columns: 2fr 1fr 1fr 1fr 1fr; gap: 48px;">
        <div>
          <img src="/images/arcascience-logo-white.svg" alt="ArcaScience" height="28" style="margin-bottom: var(--space-5);">
          <p class="arca-body-sm" style="color: rgba(255,255,255,0.65); max-width: 280px;">AI-driven benefit-risk analysis for pharmaceutical development. Founded 2018.</p>
        </div>
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Platform</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/platform-overview" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Overview</a>
            <a href="/platform-data-intelligence" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Data Intelligence</a>
            <a href="/platform-ai-models" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Decision Intelligence</a>
            <a href="/platform-outputs" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Regulatory Outputs</a>
            <a href="/security-compliance" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Security & Compliance</a>
          </nav>
        </div>
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Solutions</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/solution-therapeutic-area" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Therapeutic Areas</a>
            <a href="/ta-oncology" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Oncology</a>
            <a href="/ta-neurology" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Neurology</a>
            <a href="/ta-immunology" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Immunology</a>
            <a href="/ta-cardiology" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Cardiology</a>
            <a href="/solution-early-development" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Early Development</a>
            <a href="/solution-late-development" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Late Development</a>
          </nav>
        </div>
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Company</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/about" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">About</a>
            <a href="/leadership" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Team</a>
            <a href="/careers" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Careers</a>
            <a href="/about" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">News</a>
            <a href="/contact" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Contact</a>
          </nav>
        </div>
        <div>
          <p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Resources</p>
          <nav style="display: flex; flex-direction: column; gap: 12px;">
            <a href="/evidence-case-studies-hub" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Case Studies</a>
            <a href="/resources-whitepapers" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Whitepapers</a>
            <a href="/resources" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Blog</a>
            <a href="/resources" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Documentation</a>
          </nav>
        </div>
      </div>
      <div style="margin-top: var(--space-8); padding-top: var(--space-5); border-top: 1px solid rgba(255,255,255,0.1); display: flex; justify-content: space-between; align-items: center;">
        <p class="arca-caption" style="color: rgba(255,255,255,0.45);">&copy; 2026 ArcaScience. All rights reserved.</p>
        <div style="display: flex; gap: 24px;">
          <a href="/legal-privacy" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Privacy</a>
          <a href="/legal-terms" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Terms</a>
          <a href="/legal-cookies" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Cookies</a>
          <a href="/legal-accessibility" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Accessibility</a>
        </div>
      </div>
    </div>
  </footer>

  <button data-back-to-top aria-label="Back to top">
    <svg width="16" height="16" viewBox="0 0 16 16" fill="none"><path d="M8 12V4M4 7l4-4 4 4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round"/></svg>
  </button>

  <script src="/dist/arcascience-global.min.js" defer></script>
  <script src="/dist/arcascience-countup.min.js" defer></script>
  <script>
    document.addEventListener('DOMContentLoaded', function() {
      if (window.ArcaScience) ArcaScience.init();
      if (window.ArcaScienceCountUp) ArcaScienceCountUp.init({ selector: '[data-countup]' });
    });
  </script>
</body>
</html>